Compare AbbVie Inc (ABBV) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Total World Stock Index Fund ETF — how do they compare? AbbVie Inc trades at $253.74 (market cap $449.91B), while Vanguard Total World Stock Index Fund ETF trades at $155.5. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Total World Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| ABBV | VT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $159.35 |
52-Week Low | $184.85 | $128.41 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Vanguard Total World Stock ETF (VT) trades at $157.81, up 1.05% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings but faces overbought conditions on short-term RSI. Recent news highlights VT's global diversification advantages with over 10,000 holdings, though competitors offer lower expense ratios.
VT provides comprehensive global equity exposure but lacks available fundamental ratios in current data. The ETF's 1.6% dividend yield and broad diversification support long-term positioning, though expense ratio comparisons with peers like SCHF (0.03%) present competitive considerations for cost-conscious investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
